ClinicalTrials.gg
RecruitingNCT07042438Updated Mar 5, 2026

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

A Phase 2 interventional study of Axicabtagene Ciloleucel and Biospecimen Collection in Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements and Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by City of Hope Medical Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Lymphoma, Large B-Cell, Diffuse by City of Hope Medical Center — 7 open to participants now, 15 under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · City of Hope Medical Center.

Planned enrollment
6th of 36
56 · median 33
Started
2026
with 1 other
Phase 2
11 of 39
3 open now
Primary completion
2029-01
later than 11 of 14 live
Registered
38th of 39
by date

Among the 39 studies in Lymphoma, Large B-Cell, Diffuse by City of Hope Medical Center, this one is the 6th largest by planned enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 11 of the 14 other live ones, and was the 38th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

7 of the 39 studies in Lymphoma, Large B-Cell, Diffuse by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Lymphoma, Large B-Cell, Diffuse by City of Hope Medical Center, or all of them as a file.
02

Study summary

This phase II trial tests how well fecal microbiome transplantation works to remodel intestinal microbiota for patients with lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) with exposure to high-risk antibiotics who are receiving chimeric antigen receptor (CAR) T cells. Fecal microbiome transplantation consists of fecal microbiota from healthy donors with healthy gut microbiota that allows re-population of the patient's microbiome with diverse protective microorganisms. CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Part of the treatment for CAR T therapy involves high doses of chemotherapy. This, along with prior exposure to high strength antibiotics, can damage patient's intestinal microbiota. Giving fecal microbiome transplantation may improve clinical response by repairing intestinal microbiota for patients with relapsed or refractory lymphoma who had exposure to high-risk antibiotics.

Read the detailed description

PRIMARY OBJECTIVE:

I. Evaluate the efficacy of fecal microbiome transplant (FMT) by measuring changes in gut microbiome diversity (as assessed by Shannon alpha diversity Index) at day 0 (day of CAR T infusion).

SECONDARY OBJECTIVES:

I. Estimate rates of complete response (CR) at days +30, +90 or 1 year after CAR T therapy in each arm. (Key secondary objective) II. Determine the safety and tolerability/feasibility of fecal microbiota transplant (FMT) until 28 days post last dose by adverse events: type, frequency, severity, attribution, time course, duration.

III. Quantify engraftment of bacterial strains that are definitely attributable to FMT product.

IV. Estimate incidence and severity of cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) in each arm.

V. Shannon index at each fecal sampling timepoint after day 0 to assess overtime changes in microbiome diversity in each cohort after CAR T infusion.

VII. Estimate rates of overall response (ORR) at 30 days, 90 days and 1 year after CAR T therapy in each arm.

VIII. Determine the number of bacterial infection rate post 30 days of last FMT last dose.

IX. Estimate rate of overall survival (OS), relapse/progression and non-relapse mortality (NRM) at 30 days, 90 days and 1 year after CAR T therapy in each arm.

X. Estimate time to neutropenia recovery at each arm.

EXPLORATORY OBJECTIVES:

I. Compare quality of manufactured CAR T products in patients treated or not treated with FMT.

II. Characterize and correlate FMT treatment with the following biologic endpoints.

IIa. Plasma and stool metabolites with a focus on butyrate-related pathways (metabolomics analysis); IIb. T cell phenotype (multicolor flow cytometry at Immuno-Oncology Core) and cytokines assay (30-multiplex plate using Luminex); IIc. CAR T cell persistence (using standard polymerase chain reaction [PCR] assays) on days +30, +90, 6 months and 1 year after CAR T therapy.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo standard of care leukapheresis and receive standard of care chemotherapy and CAR T cells. Patients receive FMT orally (PO) once daily (QD) on day -10 and -7 before leukapheresis, day -10 and -7 before CAR T cell infusion, within 3 days of neutrophil recovery and 2 days after first neutrophil recovery dose. Treatment given in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.

ARM II: Patients undergo standard of care leukapheresis and receive standard of care chemotherapy and CAR T cells. Patients receive placebo PO QD on day -10 and -7 before leukapheresis, day -10 and -7 before CAR T cell infusion, within 3 days of neutrophil recovery and 2 days after first neutrophil recovery dose. Treatment given in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.

After completion of study treatment, patients are followed up at day 28, 90 and 1 year post CAR T cell therapy.

03

Conditions studied

  • Recurrent Diffuse Large B-Cell Lymphoma
  • Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
  • Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
  • Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative.

    • Assent, when appropriate, will be obtained per institutional guidelines
  • Agreement to allow the use of from diagnostic tumor biopsies

    • If unavailable, exceptions may be granted with study principal investigator (PI) approval
  • Age: ≥ 18 years
  • performance status (KPS) ≥ 60
  • Confirmed diagnosis of CD19 B-cell lymphomas of diffuse large B cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), or double-hit lymphoma (DHL) and scheduled to receive commercial CAR T treatment of YESCARTA ® for their diagnosis
  • Fully recovered from the acute toxic effects (except alopecia) to ≤ grade 1 to prior anti-cancer therapy
  • Exposure to high-risk antibiotics within 90 days of consent. High-risk broad-spectrum antibiotics include carbapenems (meropenem, imipenem, doripenem), anti-pseudomonal antibiotics (cefepime, piperacillin-tazobactam, ceftazidime) or anaerobic antibiotics including metronidazole, clindamycin, amoxicillin-sulbactam, and vancomycin
  • Clinical laboratory and organ function criteria per standard of care to CAR T patients at City of hope: (To be performed within 30 days prior to leukapheresis)
  • Seronegative for antigen (Ag)/antibody (Ab) combo, virus (HCV), active virus (HBV) (surface antigen negative)

    • HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • Meets other institutional and federal requirements for infectious disease titer requirements

    • Note: Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy
  • Women of (WOCBP): negative urine or serum pregnancy test

    • If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Agreement by females and males of childbearing potential* to use an effective method of or abstain from heterosexual activity for the course of the study through at least 12 months after the last dose of protocol therapy.

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion criteria

Exclusion Criteria:

  • Major surgery in 4 months preceding enrollment
  • No in 30 days prior to enrollment
  • Inability to swallow capsules or history of disorder with Inability to swallow FMT capsules
  • History of inflammatory bowel disorder, irritable bowel disorder
  • Severe food allergies
  • History of chronic aspiration
  • History of behavioral disorders including substance abuse disorders which per discretion of primary investigator will interfere with safe conduct and compliance to study treatment
  • History neurocognitive disorder which per discretion of primary investigator will interfere with safe conduct and compliance to study treatment
  • Diagnosis of primary immunodeficiency
  • Active second requiring treatment except non-melanoma skin cancer or carcinoma in situ-cervix, bladder or to non- prostate cancer which does not require treatment
  • Uncontrolled bacterial, fungal, or viral infection confirmed using clinical, laboratory and radiological findings requiring administration of intravenously (IV) antimicrobials
  • Any clinical, laboratory or radiologic findings per discretion of primary investigator will interfere with safe conduct of study treatment and compliance with study procedures
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Arm I (FMT)

    Patients undergo standard of care leukapheresis and receive standard of care chemotherapy and CAR T cells. Patients receive FMT PO QD on day -10 and -7 before leukapheresis, day -10 and -7 before CAR T cell infusion, within 3 days of neutrophil recovery and 2 days after first neutrophil recovery dose. Treatment given in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.

    Biological: Axicabtagene Ciloleucel · Procedure: Biospecimen Collection · Drug: Chemotherapy · Procedure: Fecal Microbiota Transplantation · Procedure: Leukapheresis

  • Placebo comparator
    Arm II (Placebo)

    Patients undergo standard of care leukapheresis and receive standard of care chemotherapy and CAR T cells. Patients receive placebo PO QD on day -10 and -7 before leukapheresis, day -10 and -7 before CAR T cell infusion, within 3 days of neutrophil recovery and 2 days after first neutrophil recovery dose. Treatment given in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.

    Procedure: Biospecimen Collection · Drug: Chemotherapy · Procedure: Fecal Microbiota Transplantation · Procedure: Leukapheresis · Drug: Placebo Administration

Interventions

  • Given CAR-T cells

    Also known as: Axi-cel, Axicel, KTE C19, KTE-C19, KTE-C19 CAR, KTEC19, Yescarta

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • DrugChemotherapy

    Receive chemotherapy

    Also known as: Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General

  • ProcedureFecal Microbiota Transplantation

    Given PO

    Also known as: Fecal Material Transplantation, Fecal Transplantation, FMT, Poo Transplant, Poop Transplant, Stool Transplant

  • ProcedureLeukapheresis

    Undergo leukapheresis

    Also known as: Leukocyte Adsorptive Apheresis, Leukocytopheresis, Therapeutic Leukopheresis, White Blood Cell Reduction Apheresis

  • DrugPlacebo Administration

    Given PO

06

What researchers measure

Primary outcomes

  1. Changes in gut microbiome diversity

    Assessed using the Shannon alpha diversity index. For comparisons at a timepoint of most interest, a t-test (or Wilcoxon rank-sum test if assumptions are not met) will be used to compare the Shannon index between the fecal microbiome transplant (FMT) and placebo groups. For over-time comparisons, linear mixed models will be used to assess longitudinal changes in microbiome diversity between treatment (FMT) and control (placebo) groups, accounting for within-subject correlations over multiple measurement points.

    Time frame: From baseline to day 0

Secondary outcomes

  1. Rate of complete response

    Time frame: At day +30, +90 and 1 year after chimeric antigen receptor t cell (CAR T) therapy

  2. Incidence of adverse events

    Scored using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 scale. Will summarize adverse events by type, severity, attribution, time of onset, duration, and association with study treatment. All observed toxicities will be tabulated and summarized by grade and frequency.

    Time frame: Up to 1 year post CAR T cell therapy

  3. Feasibility of Rx administration

    Evaluated by assessment of patient's ability to take at least 2 of the first 4 doses of Rx (4 capsules of FMT or placebo) before CAR T infusion.

    Time frame: Up to 30 days before CAR T cell infusion

  4. Quantify engraftment of bacterial strains that are definitely attributable to FMT product

    Donor microbiota engraftment will be determined by SourceTracker. SourceTracker estimates the attribution of microbiota in a post-treatment sample to donor microbiota. In choosing the donor source for each post-FMT sample, only the specific donor whose product was administered to the patient was used as donor. By contrast, because placebo capsules did not contain any donor material, the calculated engraftment rates from all four presumptive donors were averaged to derive donor attribution of post-placebo microbiota.

    Time frame: Up to 1 year post CAR T cell therapy

  5. Incidence and severity of Cytokine Release Syndrome

    Time frame: Up to 1 year post CAR T cell therapy

  6. Incidence and severity of immune effector cell associated neurotoxicity syndrome

    Time frame: Up to 1 year post CAR T cell therapy

  7. Overall response rate

    The binomial exact 95% confidence interval will be estimated at each post-treatment assessment timepoint and compared between FMT and placebo by Pearson Chi-square test or Fisher exact test.

    Time frame: At day +30, +90 and 1 year after CAR T therapy

  8. Bacterial infection rate

    Time frame: Post 30 days of last FMT last dose

  9. Rate of overall survival

    Time frame: At day +30, +90 and 1 year after CAR T therapy

  10. Rate of relapse/progression

    Time frame: At day +30, +90 and 1 year after CAR T therapy

  11. Rate of non-relapse mortality

    The binomial exact 95% confidence interval will be estimated at each post-treatment assessment timepoint and compared between FMT and placebo by Pearson Chi-square test or Fisher exact test.

    Time frame: At day +30, +90 and 1 year after CAR T therapy

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2029, 35 months after the start.

Of 211 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 35 months is below that.

Counting every sponsor, half of 264 studies reached it within 52 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 29, 2025
StartActual
Feb 11, 2026
Primary completionEst.
Jan 23, 2029
CompletionEst.
Jan 23, 2029
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07042438
Responsible party
Sponsor
First posted
Jun 29, 2025
Start date
Feb 11, 2026
Primary completion
Jan 23, 2029 (estimated)
Completion
Jan 23, 2029 (estimated)
Last update
Mar 5, 2026

Study contacts

Karamjeet S Sandhu
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axicabtagene ciloleucel

Start the discussion